ADMA Biologics (NASDAQ: ADMA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.080 | -0.100 | -0.0200 | ||||
REV | 27.690M | 29.103M | 1.413M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ADMA Biologics (NASDAQ: ADMA) through any online brokerage.
Other companies in ADMA Biologics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Outlook Therapeutics (NASDAQ:OTLK), Centessa Pharmaceuticals (NASDAQ:CNTA), Inovio Pharmaceuticals (NASDAQ:INO) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Raymond James on Thursday, November 11, 2021. The analyst firm set a price target for 5.00 expecting ADMA to rise to within 12 months (a possible 145.10% upside). 5 analyst firms have reported ratings in the last year.
The stock price for ADMA Biologics (NASDAQ: ADMA) is $2.04 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for ADMA Biologics.
ADMA Biologics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for ADMA Biologics.
ADMA Biologics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.